在临床试验中与帕金森病中安慰剂效应相关的因素:元分析
Shotaro Haji1, Wataru Sako2,3, Nagahisa Murakami1,4
1Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Journal of neurology
|July 2, 2024
概括
安慰剂效应显著影响帕金森病的临床试验. 晚期疾病,基线药物使用,更长的安慰剂期和疾病持续时间与更强的安慰剂效应有关,为未来的试验设计提供了信息.
科学领域:
- 神经学 神经学
- 临床试验设计 临床试验设计
- 药理学 药理学是指药理学的学科.
背景情况:
- 安慰剂效应可以混帕金森病 (PD) 的临床试验结果.
- 了解影响安慰剂反应的因素对于设计更强大的PD临床试验至关重要.
研究的目的:
- 在帕金森病 (PD) 临床试验中确定与安慰剂效应相关的因素.
- 为在未来的PD研究中尽量减少安慰剂影响提供指导.
主要方法:
- 对38篇文章进行了元分析,涉及4828名受试者.
- 在统一帕金森病评分表第三部分 (UPDRS III) 或运动障碍学会赞助的UPDRS III (MDS-UPDRS III) 修订中对安慰剂的影响进行了聚合.
- 分析的变量包括疾病阶段,基线药物,安慰剂运行期和试验持续时间.
主要成果:
- 观察到一个显著的整体安慰剂效应 (SMD = -0.25,p < 0.001).
- 安慰剂效应与晚期PD (p=0.04),基线药物暴露 (p<0.001),安慰剂服用期间 (p<0.001) 和疾病持续时间 (p<0.01) 有显著关联.
结论:
- 诸如晚期疾病,基线药物使用和更长的安慰剂服用周期等因素会影响PD试验中的安慰剂效应.
- 这些发现对于优化未来临床试验设计以减轻安慰剂影响至关重要.
相关概念视频
01:54The Placebo Effect
6.1K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.1K
01:24Parkinson's Disease: Treatment
254
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
254
01:15Parkinson's Disease: Overview
523
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
523
02:07Blind Procedures
10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K
01:37Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
01:11Blinding
2.4K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.4K